Drugs in the Pipeline NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated Publish Date May 12, 2020 Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
Drugs in the Pipeline Pipeline: Investigational Therapies for COVID-19 Publish Date April 13, 2020 Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.